IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis

Molecular pathogenesis of IDH mutations in gliomas

(2012) Koichi Ichimura   Brain Tumor Pathology

Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas

(2012) Xiao-Wei Wang et al.   CANCER

Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme

(2012) Wei Zhang et al.   CANCER

Emerging insights into the molecular and cellular basis of glioblastoma

(2012) G. P. Dunn et al.   GENES & DEVELOPMENT

Glioblastoma Multiforme

(2012) Kevin Anton et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas

(2012) T. A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

IDH Mutations in Human Glioma

(2012) Won Kim et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China

(2012) Wei Yan et al.   PLoS One

Current concepts and management of glioblastoma

(2011) Matthias Preusser et al.   ANNALS OF NEUROLOGY

Glioblastoma biomarkers from bench to bedside: advances and challenges

(2011) Gina Farias-Eisner et al.   BRITISH JOURNAL OF NEUROSURGERY

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients

(2011) Akitake Mukasa et al.   CANCER SCIENCE

Role of isocitrate dehydrogenase in glioma

(2011) Brian M Alexander et al.   Expert Review of Neurotherapeutics

Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications

(2011) R. Gupta et al.   JOURNAL OF CLINICAL PATHOLOGY

Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis

(2011) Robert A. Olson et al.   JOURNAL OF NEURO-ONCOLOGY

The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

(2010) Fonnet E. Bleeker et al.   ACTA NEUROPATHOLOGICA

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism

(2010) Z. J. Reitman et al.   JNCI-Journal of the National Cancer Institute

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

(2010) K E Yen et al.   ONCOGENE

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

(2008) Monika E. Hegi et al.   JOURNAL OF CLINICAL ONCOLOGY

Psychosocial and supportive-care needs in high-grade glioma

(2008) Susan Catt et al.   LANCET ONCOLOGY